Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-101 vs Stalevo in Parkinson's Disease
NCT01766258Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- May 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ODM-101 in Parkinson's disease (PD), sponsored by Orion Corporation. Started May 2011; status: completed.
02
Drugs
ODM-101
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01766258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766258.